Ebromin p

All forms of tracheobronchitis, emphysema with bronchitis pneumoconiosis, chronic inflammatory pulmonary conditions, bronchiectasis, bronchitis with bronchospasm asthma. During acute exacerbations of bronchitis it should be given with the appropriate antibiotic.

Clenbuterol (Ebromin p) should not be applied during the first 3 months of pregnancy. It should be administered cautiously to pregnant women on account of its tocolytic action.

The effect of Clenbuterol (Ebromin p) may be decreased and the bronchodilaing effect may even disappear during combined therapy with betaadrenergic blockers. Simultaneous administartion of Clenbuterol (Ebromin p) with cardiac glucosides provokes disturbances of the cardiac rhythm and increases their toxicity. Rhythmic disturbances are also observed after combined therapy with MAO-inhibitors and theophylline. Clenbuterol (Ebromin p) weakens the effects of insulin and sulfanylurea antidiabetic drug. Clenbuterol (Ebromin p) and sympatomimetics potentiate mutually their toxicity

Tremor of the limbs, anxiety and tachycardia may be observed very rarely in the initial stage of treatment, disappearing after the dose is reduced.